Injective CEO rings Nasdaq bell as Canary’s staked INJ ETF begins trading

Injective has entered the U.S. exchange-traded fund market after Canary Capital launched its staked INJ ETF on Nasdaq, with the fund reaching $16.12 million in net assets during its first two trading sessions. Summary Canary Capital launched its staked Injective ETF on Nasdaq, giving investors access to INJ exposure. Injective CEO Eric Chen joined Canary Capital’s Steven McClurg for Nasdaq’s November 6 opening ceremony. INJC reported $16.12 million in assets by Friday, with 600,000 fund shares still outstanding overall. The fund seeks staking rewards through Injective validators, with net earnings reflected in asset value. Injective traded near $8.10 on November 9 after gaining more than 12% over seven days. According to Nasdaq’s announcement, Injective Labs CEO Eric Chen joined Canary Capital CEO Steven McClurg to ring the opening bell on November 6, one day after the fund began trading under the ticker INJC. The ceremony followed the introduction of a product that combines direct exposure to Injective’s native cryptocurrency with participation in network staking. Unlike a conventional spot cryptocurrency fund, INJC seeks to earn additional tokens through Injective’s proof-of-stak...